Meeting
2015 ASCO Annual Meeting
A phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (pts) with metastatic solid tumors.
Authors
Rahul Raj Aggarwal
UC San Francisco, San Francisco, CA
Rahul Raj Aggarwal , Jennifer A. Grabowsky , Anne Reinert , Scott Thomas , Thach-Giao Truong , Christina Chun , Pamela N. Munster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Epigenetics
Clinical Trial Registration Number
NCT01543763
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2560)
DOI
10.1200/jco.2015.33.15_suppl.2560
Abstract #
2560
Poster Bd #
276
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (Pts) with metastatic solid tumors.
First Author: Rahul Raj Aggarwal
Poster
2013 ASCO Annual Meeting
Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.
First Author: Thach-Giao Truong
Poster
2016 ASCO Annual Meeting
Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: A phase 1 study in advanced solid tumor malignancies.
First Author: Rahul Raj Aggarwal
Poster
2016 ASCO Annual Meeting
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
First Author: Todd Michael Bauer